

# **EXHIBIT B**

IN THE CIRCUIT COURT, SEVENTEENTH JUDICIAL CIRCUIT,  
IN AND FOR BROWARD COUNTY, FLORIDA

CASE NO.:  
DIVISION:

ROBYNE NEWELL,

Plaintiff,

CLASS REPRESENTATION

vs.

PETSMART, INC., a Foreign  
For-Profit Corporation

Defendant.

**CLASS ACTION COMPLAINT**

Plaintiff, ROBYNE NEWELL similarly situated in Florida, by and through her undersigned counsel, hereby files this Class Action Complaint, against Defendant, PETSMART, INC. (hereinafter referred to as "PetSMART" or "Defendant"), and in support thereof alleges as follows:

**I. PARTIES, JURISDICTION AND VENUE**

1. This is a class action for damages pursuant to Florida Rule of Civil Procedure 1.220(b) in excess of Thirty Thousand Dollars (\$30,000.00) exclusive of interest, costs and attorney's fees.

2. Plaintiff is an individual consumer over the age of eighteen, who resides in Broward County Florida. Plaintiff seeks injunctive relief and damages on behalf of Plaintiff and the Class, and respectfully requests a jury trial on damage claims.

3. Defendant is a foreign for-profit corporation, doing business in Broward County, Florida.



4. Venue for this action properly lies in Broward County, Florida, pursuant to the provisions of Section 47.051, Fla. Stat. and Chapter 501.207 et seq. Fla. Stat. because Defendant transacts business in Broward County, Florida and the transactions out of which this action arose occurred in Broward County, Florida.

5. There is not federal jurisdiction of this Action under the Class Action Fairness Act of 2005 ("CAFA"), Pub. L. No. 109-2, 119 Stat. 4 (2005), which explicitly provides for the original jurisdiction of the Federal Courts of any class action in which any member of the plaintiff class is a citizen of a state different from any Defendant, and in which the matter in controversy exceeds in the aggregate the sum of \$5,000,000.00, exclusive of interest and costs. The issue at hand does not exceed this requisite amount.

#### **IV. FACTUAL ALLEGATIONS**

6. On or about April 23, 2020, Plaintiff purchased Only Natural Pet Hemp Calming Support, listed as containing 60 Hemp Soft Chews (hereinafter also referred to as "Product"), from PETSMART located at 1700 N. Federal Highway, Fort Lauderdale, Florida. A copy of the receipt is attached hereto as **Exhibit "A."**

7. The Product had not been altered between manufacture and point of sale. A photograph of the Product's packaging is attached hereto as composite **Exhibit "B."**



8. The front of the Product's packaging states: "Powerful blend of hemp seed, chamomile & magnesium" and that it contains "Soft Chews for Dogs." See Exhibit "B."

9. The back of the Product's packaging states:

- "Hemp Seed Oil Balanced source of Omega 3 & 6 supports healthy brain function."
- "Chamomile & Lemon Balm Natural herbs effectively help to relieve stress and anxiety."
- "Theanine Promotes relaxation and balanced behavior without drowsiness."
- "Magnesium Supports the nervous system and promotes a healthy response to stress. See Exhibit "B."

10. The back of the packaging, provides dosage instructions based on the weight of the dog and also states: "Use to manage stressful situations like vet or groomer visits, road trips, thunderstorms and separation anxiety." See Exhibit "B."

11. The product is also advertised on Defendant's website at: <https://www.petsmart.com/dog/dental-care-and-wellness/treatments/only-natural-pet-hemp-calming-support-soft-dog-chews-5296089.html>.

12. Screenshots of Defendant's website advertising and marketing the Product to consumers is attached hereto as composite **Exhibit "C."**



13. Defendant's website also advertises and represents that the Product contains chews that "are used to manage stressful situations like vet or groomer visits, road trips, thunderstorms and separation anxiety." See Ex. "C."

14. Defendant's website also advertises and represents that the "**Health Consideration**" for which the Product is designed and intended for are "Calming, Stress & Anxiety Relief." See Ex. "C."

15. The Product's packaging, as well as Defendant's advertising and marketing of the Product, makes clear that the Product's contents are intended to treat, mitigate, or prevent disease and/or are intended to affect the structure or any function of the body; specifically, to provide calming, stress and anxiety relief to dogs.

16. At all material times, Defendant, PetSmart, was a retailer selling, marketing, and distributing the Product.

17. The Product, according to its explicit advertising, marketing, labeling and packaging, is clearly intended mitigate, treat, or prevent disease in animals, and therefore are drugs within the meaning of section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B).

18. Additionally, the Product, according to its explicit advertising, marketing, labeling and packaging, is a "new animal drugs" under section 201(v) of the FD&C Act, 21 U.S.C. 321(v), because it is not the subject of a final FDA regulation published through notice and comment rulemaking finding that the drug has been generally recognized among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe



and effective for use under the conditions prescribed, recommended, or suggested in the labeling.

19. To be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or a listing on the Index of Legally Marketed Unapproved New Animal Drugs for Minor Species ("index listing") under section 512, 571, or 572 of the FD&C Act [21 U.S.C. § 360b, 360ccc, or 360ccc-1], respectively

20. New animal drugs that lack the required approval or index listing are "unsafe" and "adulterated" under sections 512(a) and 501(a)(5) of the FD&C Act [21 U.S.C. §§ 360b(a) and 351(a)(5)]. Introduction of an adulterated animal drug into interstate commerce is prohibited under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].

21. The Product is not approved by the FDA or indexed and therefore the Product is considered unsafe under section 512(a) of the FD&C Act, 21 U.S.C. 360b(a), and adulterated under section 501(a)(5) of the FD&C Act, 21 U.S.C. 351(a)(5).

22. The FDA has sent numerous warning letters to companies manufacturing, advertising and marketing products that are intended mitigate, treat, or prevent disease in animals and/or "new animal drugs" Examples of some of these warning letters can be viewed at: <https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/curaleaf-inc-579289-07222019>; <https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/curaleaf-inc-579289-07222019>



and-criminal-investigations/warning-letters/dr-gs-marine-aquaculture-inc-606979-04152020; and are also attached hereto as **Exhibit “D.”**

23. For these reasons, the Product is an unapproved new animal drug and cannot lawfully be sold.

24. The introduction or delivery for introduction into interstate commerce of the Product, as a misbranded drug, violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).

25. A Product that cannot lawfully be sold has no value. *Debernardis v. IQ Formulations, LLC*, D.C. Docket No. 1:17 – cv -21562-DPG (11th Cir. Nov. 14, 2019) (finding a claim under FDUTPA should survive a motion to dismiss where the plaintiff purchased a product which was subject to an FDA warning letter to the manufacturer that the product could not lawfully be sold).

26. Defendant, in its respective role as a distributor, was aware of and disregarded these laws when it advertised, marketed, and/or sole the Product at its stores.

27. Defendant’s actions of advertising, marketing, and/or selling an unapproved and/or misbranded new drug constitutes false and deceptive conduct.

28. Defendant did not disclose to consumers, including Plaintiff and putative Class Members, that the Product could not lawfully be sold because it was an unapproved new animal drug and/or because it was misbranded.



29. When purchasing the Product, consumers were misled into believing Defendant had complied with applicable laws and regulations and that Defendant could lawfully sell the Product.

30. Defendants intended for Plaintiff and putative Class Members to be misled.

31. Defendant's misleading and deceptive practices proximately caused harm to Plaintiff and Class Members. Defendant has sold Products that are unapproved and/or misbranded and are worthless because they could not be lawfully sold to consumers.

32. The Product's labeling, marketing, and advertising, as outlined and explained above, contain representations which are misleading and deceptive and that are likely to mislead a consumer acting reasonably in the circumstances to her detriment by purchasing a Product the consumer would reasonably believe was legally sold, approved, and properly branded in accordance with applicable law and regulations.

33. In reliance on the Product label, marketing, and advertising, as well as Defendant's actions of offering the Product for sale, the Plaintiff, a consumer, reasonably believed she was purchasing a Product that was could legally be sold.

34. Plaintiff is aggrieved by the deceptively labeled and marketed Product as she relied on the misleading and deceptive marketing and advertising and she was deprived of the benefit of the bargain she reasonably anticipated from the Product's marketing, advertising, and sale; specifically, she was



deprived of the benefit she paid for a Product she reasonably believed was legally sold and properly branded.

35. Reasonable consumers, such as the Plaintiff, will continue to be aggrieved by the deceptive and misleading marketing, advertising, and sale of the Product as reasonable consumers will continue to make the plausible connection that they are purchasing a Product that can legally be sold and that is properly branded.

36. Defendant unlawfully marketed, advertised, sold, and/or distributed the Product to Florida purchasers.

37. Defendant's false and misleading representations and omissions deceive Florida consumers for the reasons previously alleged, above.

38. Plaintiff has performed all conditions precedent to bringing this Action.

39. As an immediate, direct, and proximate result of Defendant's false, misleading, and deceptive representations and conduct, Defendant injured Plaintiff and the other Class members in that Plaintiff and other Class members:

- a. paid a sum of money for the Products that was not as represented;
- b. paid a premium price for the Products that was not as represented;
- c. were deprived the benefit of the bargain because the Products they purchased was different than what Defendant warranted;
- d. were deprived the benefit of the bargain because the Products they purchased had less value than what was represented by Defendant;



- e. did not receive a Products that measured up to their expectations as created by Defendant;
- f. purchased a Product that was other than what was represented by Defendant;
- g. purchased a Product that Plaintiff and the other members of the Class did not expect or consent to;
- h. purchased a Product that was of a lower quality than what Defendant promised;
- i. were denied the benefit of knowing what they purchased.

40. Had Defendant not made the false, misleading, and deceptive representations and omissions, or engaged in false, misleading, and deceptive conduct, Plaintiff and the other Class members would not have been economically injured because Plaintiff and the other Class members would not have purchased the Product.

41. Accordingly, Plaintiff and the other Class members have suffered injury in fact and lost money or property as a result of Defendant's wrongful conduct.

42. Plaintiff and the other Class members did not obtain the full value of the advertised Product due to Defendant's misrepresentations and omissions.

43. Plaintiff and the other Class members purchased, purchased more of, or paid more for the Product than they would have done had they known the truth about the Product.



### **ANTICIPATED DEFENSE**

44. In anticipation of a defense that may be raised by Defendant, and only in response to that anticipated defense, Plaintiff pleads that in addition to violating Florida consumer protection laws, the Product also fails to comply with applicable federal law, as alleged previously.

### **V. CLASS ALLEGATIONS**

45. Plaintiff re-alleges and incorporates by reference the allegations set forth in each of the preceding paragraphs of this *Class Action Complaint* as if fully set forth herein.

46. Pursuant to Rule 1.220, *Florida Rules of Civil Procedure*, Plaintiff brings this class action and seeks certification of the claims and certain issues in this action on behalf of a Class defined as:

**All persons throughout Florida, who, within the four years preceding the filing the original Complaint ("Class Period"), purchased one or more of the Product from Defendant ("Class") with a credit or debit account .**

47. Excluded from the Class is Defendant, its subsidiaries, affiliates, and employees; all persons who make a timely election to be excluded from the Class; governmental entities; and the Judge(s) to whom this case is assigned and any immediate family members thereof.

48. Certification of Plaintiff's claims for class-wide treatment is appropriate because Plaintiff can prove the elements of Plaintiff's claims on a class-wide basis using the same evidence as would be used to prove those claims in individual actions alleging the same claims.



**A. Numerosity**

49. The members of the Class are so numerous that individual joinder of all class members is impracticable.

50. The precise number of members of the Class is unknown to Plaintiff, but it is clear that the number greatly exceeds the number that would make joinder practicable, particularly given Defendant's comprehensive distribution and sales network throughout Florida.

51. Members of the Class may be notified of the pendency of this action by recognized, Court-approved notice dissemination methods, which may include U.S. Mail, electronic mail, Internet postings, and/or published notice.

**B. Commonality and Predominance**

52. This action involves common questions of law or fact, which predominate over any questions affecting individual members of the Class. All members of the Class were exposed to Defendant's deceptive and misleading advertising and marketing claims and omissions, and/or Defendant's deceptive and misleading conduct, alleged herein.

53. Furthermore, common questions of law or fact include:

- a. whether Defendant engaged in the conduct as alleged herein;
- b. whether Defendant's practices violate applicable law cited herein;
- c. whether Plaintiff and the other members of the Class are entitled to actual, statutory, or other forms of damages, and/or other monetary relief; and



- d. whether Plaintiff and the other members of the Class are entitled to equitable relief, including but not limited to injunctive relief.

54. Defendant engaged in a common course of conduct in contravention of the laws Plaintiff seeks to enforce individually, and on behalf of the other members of the Class. Similar or identical statutory legal violations, business practices, and injuries are involved. Individual questions, if any, pale by comparison, in both quality and quantity, to the numerous common questions that dominate this action. Moreover, the common questions will yield common answers.

#### **C. Typicality**

55. Plaintiff's claims are typical of the claims of the other members of the Class because, among other things, all members of the Class were comparably injured through the same uniform misconduct described herein. Further, there are no defenses available to Defendant that are unique to Plaintiffs.

#### **D. Adequacy of Representation**

56. Plaintiff is an adequate representative of the members of the Class because Plaintiff's interests do not conflict with the interests of the other members of the Class that Plaintiff seeks to represent. Plaintiff has retained counsel competent and experienced in complex class action litigation and Plaintiff will prosecute this action vigorously. The Class' interests will be fairly and adequately protected by Plaintiff and Plaintiff's counsel. Undersigned counsel has represented consumers in a wide variety of actions where they have



sought to protect consumers from fraudulent and deceptive practices.

**E. Declaratory and Injunctive Relief**

57. Defendant has acted or refused to act on grounds generally applicable to Plaintiff and the other members of the Class, thereby making appropriate final injunctive relief and declaratory relief, as described herein, with respect to the members of the Class as a whole.

**F. Superiority**

58. A class action is superior to any other available means for the fair and efficient adjudication of this controversy, and no unusual difficulties are likely to be encountered in the management of this class action. The damages or other financial detriment suffered by Plaintiff and the other members of the Class are relatively small compared to the burden and expense that would be required to individually litigate their claims against Defendant, so it would be impracticable for members of the Class to individually seek redress for Defendant's wrongful conduct. Even if the members of the Class could afford individual litigation, the court system could not. Individualized litigation creates a potential for inconsistent or contradictory judgments, and increases the delay and expense to all parties and the court system and thereby unnecessarily clogging of dockets.

59. By contrast, the class action device presents far fewer management difficulties and provides the benefits of single adjudication, economy of scale, and comprehensive supervision by a single court. Given the similar nature of the members of the Class' claims and the absence of material or dispositive differences in laws upon which the claims are based, the Class will be



easily managed by the Court and the parties.

**FIRST CAUSE OF ACTION:**  
**VIOLATION OF THE FLORIDA DECEPTIVE AND UNFAIR TRADE**  
**PRACTICES ACT, FLA. STAT. § 501.201 et seq.**

60. Plaintiff re-alleges and incorporates by reference the allegations set forth in the preceding paragraphs of this Complaint as if fully set forth herein verbatim.

61. This cause of action is brought pursuant to the Florida Deceptive and Unfair Trade Practices Act, Sections 501.201 to 501.213, *Florida Statutes*.

62. The express purpose of FDUTPA is to “protect the consuming public . . . from those who engage in unfair methods of competition, or unconscionable, deceptive, or unfair acts or practices in the conduct of any trade or commerce.” Section 501.202(2), *Florida Statutes*.

63. Section 501.204(1), *Florida Statutes* declares as unlawful “unfair methods of competition, unconscionable acts or practices, and unfair or deceptive acts or practices in the conduct of any trade or commerce.”

64. The sale of the Product at issue in this cause was a “consumer transaction” within the scope of FDUTPA.

65. Plaintiff is a “consumer” as defined by Section 501.203, *Florida Statutes*.

66. The Product sold by Defendant is a good within the meaning of FDUTPA and Defendant is engaged in trade or commerce within the meaning of FDUTPA.

67. For the reasons discussed herein, Defendant violated and



continues to violate FDUTPA by engaging in unconscionable, deceptive, unfair acts or practices proscribed by Section 501.201, *Florida Statute*, et. seq.

68. Defendant's actions of misrepresenting and omitting material facts regarding the Product—that it could not lawfully be sold as it was an unapproved new animal drug and/or a misbranded drug—constitute unconscionable, deceptive, or unfair acts or practices, and are immoral, unethical, oppressive, and unscrupulous activities that are substantially injurious to consumers in violation of FDUTPA. Defendant knew or should have known that the product could not be lawfully sold to consumers, and Defendant failed to disclose this information to consumers.

69. Plaintiff and putative Class Members suffered damages when they purchased the Product, which could not lawfully be sold to consumers. Defendant's unconscionable, deceptive, and/or unfair practices caused actual damages to Plaintiff and putative Class Members who were unaware of this when they purchased the Product.

70. Defendant's affirmative misrepresentations, omissions, actions, and practices described herein were likely to, and did in fact, deceive and mislead members of the public, including consumers acting reasonably under the circumstances, to their detriment.

71. Consumers, including Plaintiff and putative Class Members, could not have purchased the Product had Defendant disclosed to them and the consuming public that the Product could not lawfully be sold to consumers because it was an unapproved new animal drug and because it was misbranded.



72. As a direct and proximate result of the unconscionable, unfair, and deceptive acts or practices alleged herein, Plaintiff and putative Class Members have been damaged and are entitled to recover actual damages to the extent permitted by law, including class action rules, in an amount to be proven at trial.

73. Plaintiff and Class Members have been aggrieved by Defendant's unfair and deceptive practices in violation of FDUTPA, in that they purchased Defendant's deceptively labeled, marketed, and advertised the Product.

74. Reasonable consumers rely on Defendant to honestly market and advertise the Product to consumers by selling a Product that can legally be sold and that is properly branded.

75. Defendant has deceived reasonable consumers, like Plaintiff and the Class, into believing the Product was something it was not; specifically that the Product could legally be sold and/or that it was properly branded.

76. In addition, Plaintiff and the putative Class seeks equitable relief and injunctive relief against Defendant on terms that the Court considers reasonable, and reasonable attorneys' fees, litigation costs, and expenses.

77. Plaintiff and the Class suffered damages and are entitled to injunctive relief.

78. Pursuant to sections 501.211(2) and 501.2105, *Florida Statutes*, Plaintiff and the Class make claims for damages, attorney's fees and costs. The damages suffered by the Plaintiff and the Class were directly and proximately caused by the deceptive, misleading and unfair practices of Defendant. Additionally, pursuant to Section 501.211(1), *Florida Statutes*, Plaintiff and the



Class seek injunctive relief for, *inter alia*, the Court to enjoin Defendant's above-described wrongful acts and practices, and for restitution and disgorgement.

79. Plaintiff seeks all available remedies, damages, and awards as a result of Defendant violations of FDUTPA.

### **PRAYER FOR RELIEF**

**WHEREFORE**, Plaintiff, individually, and on behalf of all others similarly situated, prays for relief pursuant to each cause of action set forth in this Complaint as follows:

i. For an order certifying that the action may be maintained as a class action, certifying Plaintiff as representative of the Class, and designating Plaintiff's attorneys Class counsel;

ii. For an award of equitable relief for all causes of action as follows:

a. Enjoining Defendant from continuing to engage, use, or employ any unfair and/or deceptive business acts or practices related to the design, testing, manufacture, assembly, development, marketing, advertising, or sale of the Products for the purpose of selling the Products in such manner as set forth in detail above, or from making any claims found to violate FDUTPA or the other causes of action as set forth above;

b. Restoring all monies that may have been acquired by Defendant as a result of such unfair and/or deceptive act or practices; and



- iii. For actual damages in an amount to be determined at trial for all causes of action;
- iv. For an award of attorney's fees and costs;
- v. For any other relief the Court might deem just, appropriate, or proper; and
- vi. For an award of pre- and post-judgment interest on any amounts awarded.

### **DEMAND FOR JURY TRIAL**

Plaintiff hereby demands trial by jury on all issues so triable.

Submitted: April 28, 2020.

By: /s/ Howard W. Rubinstein  
Howard W. Rubinstein, Esq.  
The Law Office of Howard W.  
Rubinstein  
1281 N. Ocean Dr. Apt. 198  
Singer Island, FL 33404  
Telephone: 832-715-2788  
Fax: 561-688-0630  
Email: howardr@pdq.net





PETSMART #2183  
 1700 N Federal Highway  
 Fort Lauderdale, FL 33305-2543  
 954-563-0140  
 visit us at PetSmart.com

SALE T-7379 C-101101 2183/101  
 COMMUNITY CASHIER-521240

0173725776388 GC 10LT		3.29
REG PRICE	3.29	
(RETURN PRICE	3.23 EA)	

0081000641039 HMP CLM SC60		17.99
REG PRICE	17.99	
(RETURN PRICE	17.93 EA)	

SUBTOTAL		21.28
TAXABLE AMOUNT	21.28	
NON-TAXABLE AMOUNT	0.00	

TAX 7.000%	1.49
<b>TOTAL</b>	<b>22.77</b>


CASH	
TOTAL ITEMS SOLD: 2	23.00
TOTAL ITEMS RETURNED: 0	
CHANGE DUE	0.23

RECEIPT VALID THROUGH- 06/22/2020




7379 2183 101 04232020












events | gift card | local ad | track your order **9,248,538 lives saved.** sign up, earn points, get treats




Order today, get it today! **SAVE 10%** when you pickup in store or curbside - exclusions apply\* >



shop by brand | shop by pet | pet services | sale | help



Order today, get it today! **SAVE 10%** when you pickup in store or curbside - exclusions apply\* >

Dog / Dental Care & Wellness / Treatments



## Only Natural Pet® Hemp Calming Support Soft Dog Chews

by Only Natural Pet

Item #5296089 ★★★★★

**\$32.99** ~~\$33.99~~

Earn Treats on this purchase! Sign Up

SAVE 20% off Calming Products with code **CHILLAX**

SAVE 10% With Buy Online, Pickup in Store or Curbside Pickup!

Details

FEEDBACK

Quantity

120 Count

+ - C



Buy online, pick up in-store

Take advantage of our Curbside service by calling the store when you arrive.



**LOW STOCK AT****Lake Wales****24005 US Highway 27****863-855-9297****Check other nearby stores**

1

**Buy & Pickup**

♥ Estimated 263 points earned

or

**Ship to me** ⓘ**Ship**

♥ Estimated 263 points earned

**This item is temporarily unavailable****Description****Directions****DESCRIPTION**

Keep your dog calm in normally stressful situations with the help of Only Natural Pet Hemp Calming Soft Chews. These hemp calming dog chews may be used to manage stressful situations like vet or groomer visits, road trips, thunderstorms, or separation anxiety.

**Features:**

- Holistic veterinarian formulated
- THC Free
- No sweeteners, artificial flavors, colors or preservatives
- 100% satisfaction guarantee
- Hemp Seed Oil: Balanced source of Omega-3 & 6 supports healthy brain function
- Chamomile & Lemon Balm: Natural herbs selectively help to relieve stress and anxiety
- L-Theanine: Promotes relaxation and balanced behavior without drowsiness
- Magnesium: Naturally supports the nervous system to help feel less stressed and more relaxed

**Intended For:** Dogs
**FEEDBACK**  




**Includes:** 1 Jar - 120 soft chews

**Health Consideration:** Calming Support

**Pet Weight:** All

**Total Weight:** 0.92 LBS (0.42 kg)

**Dimensions:** 3.5 in x 3.5 in x 6.25 in

**Cautions:** Safe use in pregnant animals or animals intended for breeding has not been proven. If animal's condition worsens or does not improve, stop product administration and consult your veterinarian. An examination from a veterinarian is recommended prior to using this product. For animal use only. Do not use if product appears tampered with. Keep out of the reach of children and animals. In case of accidental overdose, contact a health professional immediately.

## Pet Parents Also Bought



**Only Natural Pet®  
Hemp Allergy, Skin &  
Coat Soft Dog Chews**

2 Sizes

**\$17.99 - 31.99**



**Only Natural Pet®  
Hemp Hip & Joint  
Support Soft Dog**

2 Sizes

**\$19.99 - 29.99**



**ThunderShirt®  
Insanely Calm™ Dog  
Anxiety Shirt**

6 Sizes

**\$39.99 - 44.99**

~~\$44.99 - 44.99~~

FEEDBACK

null

★★★★★ 3.9 32 Reviews

Search topics and reviews



32  
Reviews

32  
Questions

11  
Answers



**WARNING LETTER**

**Curaleaf, Inc**

**MARCS-CMS 579289 – JULY 22, 2019**

**Delivery Method:**

Via Overnight Delivery

**Product:**

Animal & Veterinary  
Drugs

**Recipient:**

Joseph Lusardi  
President  
Curaleaf, Inc  
301 Edgewater Place Suite 405  
Wakefield, MA 01880  
United States

**Issuing Office:**

Center for Drug Evaluation and Research  
10903 New Hampshire Avenue,  
Silver Spring, MD 20993  
United States

**WARNING LETTER**

**VIA OVERNIGHT DELIVERY  
RETURN RECEIPT REQUESTED**

July 22, 2019

Joseph Lusardi, President  
Curaleaf, Inc.  
301 Edgewater Place  
Suite 405  
Wakefield, MA 01880

**RE: 579289**



Dear Joseph Lusardi:

This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address <https://curaleafhemp.com> in April and June 2019 and has determined that you take orders there for the products "CBD Lotion," "CBD Pain-Relief Patch," "CBD Tincture" (5 versions), "CBD Disposable Vape Pen" (5 versions) and "Bido CBD for Pets" (3 versions), all of which you promote as products containing cannabidiol (CBD).<sup>1</sup> We have also reviewed your social media websites at [www.facebook.com/CuraleafHemp](http://www.facebook.com/CuraleafHemp) and <https://twitter.com/curaleafhemp>; these websites direct consumers to your website, <https://curaleafhemp.com>, to purchase your products. FDA has determined that your "CBD Lotion," "CBD Pain-Relief Patch," "CBD Tincture," and "CBD Disposable Vape Pen" products are unapproved new drugs sold in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), 21 U.S.C. 355(a) and 331(d). Furthermore, these products are misbranded drugs under section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1). FDA has also determined that your "Bido CBD for Pets" products are unapproved new animal drugs that are unsafe under section 512(a) of the FD&C Act, 21 U.S.C. 360b(a), and adulterated under section 501(a)(5) of the FD&C Act, 21 U.S.C. 351(a)(5). As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the FD&C Act. You can find the FD&C Act and FDA regulations through links on FDA's home page at [www.fda.gov](http://www.fda.gov).

#### **Unapproved New and Misbranded Human Drug Products**

Based on our review of your website, your "CBD Lotion," "CBD Pain-Relief Patch," "CBD Tincture," and "CBD Disposable Vape Pen" products are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or intended to affect the structure or any function of the body.

Examples of claims observed on your website and social media accounts in April 2019 that establish the intended use of your products as drugs include, but may not be limited to, the following:

On your product webpage for CBD Disposable Vape Pen (Relieve):

- "[F]or chronic pain."

On your product webpage for CBD Tincture (Relieve):

- "[S]oothing tincture for chronic pain."

Additional claims observed on your website in June 2019 include, but are not limited to, the following:

On your webpage titled "Can CBD Oil be Used for ADHD?"

- "CBD oil is becoming a popular, all-natural source of relief used to address the symptoms of many common conditions, such as chronic pain, anxiety . . . ADHD."
- "The Benefits of CBD Oil for ADHD . . . It's not unusual for people with ADHD to feel anxious and on the edge. CBD is known for its anti-anxiety properties that can promote relaxation and stress relief. It can also help to restore focus and ability to concentrate on specific tasks, as well as reduce impulsivity."

On your webpage titled "How to Use CBD Oil for Anxiety"

- "CBD can successfully reduce anxiety symptoms, both alone and in conjunction with other treatments."
- "CBD oil can be used in a variety of ways to help with chronic anxiety."



On your webpage titled "CBD Benefits: Top 5 Research-Backed Benefits of CBD"

- "CBD has also been shown to be effective in treating Parkinson's disease."
- "CBD has been linked to the effective treatment of Alzheimer's disease . . ."
- "CBD is being adopted more and more as a natural alternative to pharmaceutical-grade treatments for depression and anxiety."
- "CBD can also be used in conjunction with opioid medications, and a number of studies have demonstrated that CBD can in fact reduce the severity of opioid-related withdrawal and lessen the buildup of tolerance."
- "CBD has been demonstrated to have properties that counteract the growth of spread of cancer."
- "CBD was effective in killing human breast cancer cells."
- "Heart disease is one of the leading causes of death in the United States each year, and CBD does a number of things to deter it. The two most important of these are the ability to lower blood pressure, and the ability to promote good cholesterol and lower bad cholesterol."

On your webpage titled "Hemp Oil vs. CBD Oil: Everything You Need to Know"

- "CBD . . . can be used to help manage a wide range of health conditions, such as . . . Anxiety and depression . . . Chronic or arthritic pain . . ."

On your webpage titled "How to Choose the Best CBD Oil for You"

- "Some of the most common reasons to use CBD oil include . . . Chronic pain . . . Mental conditions like anxiety, depression, and PTSD . . ."

On your webpage titled "Is CBD Oil Good for Depression?"

- "A 2014 study showed that participants who received CBD oil experienced anti-anxiety and anti-depression effects from the oil."
- "A 2018 study showed that CBD offers quick relief of depression and anxiety symptoms and that the residual effects can last up to seven days."

On your webpage titled "What are the Benefits of Hemp-Derived CBD Oil?"

- "What are the benefits of CBD oil? . . . Some of the most researched and well-supported hemp oil uses include . . . Anxiety, depression, post-traumatic stress disorders, and even schizophrenia . . . Chronic pain from fibromyalgia, slipped spinal discs . . . Eating disorders and addiction . . ."

On your Facebook Social Media Account:

- April 8, 2019 posting – "CBD Can be a powerful ally if you're suffering from chronic inflammation and pain."
- March 14, 2019 posting – "The top five research backed benefits of CBD include: 1) neuro[de]generative disease 2) depression and anxiety treatment 3) pain treatment 4) aids in the treatment of cancer and related symptoms to cancer . . ."

On your Twitter Social Media Account:

- March 27, 2019 posting – "#ICBD to help lower anxiety . . ."

March 25, 2019 posting – "CBD is being adopted more and more as a natural alternative to pharmaceutical-grade treatments for depression and anxiety."

Your "CBD Lotion," "CBD Pain-Relief Patch," "CBD Tincture," and "CBD Disposable Vape Pen" products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are "new drugs" under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). New drugs may not be legally introduced or



delivered for introduction into interstate commerce without prior approval from the FDA, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.

Your “CBD Lotion,” “CBD Pain-Relief Patch,” “CBD Tincture,” and “CBD Disposable Vape Pen” products are also misbranded within the meaning of section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1), in that their labeling fails to bear adequate directions for use. “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended, 21 CFR 201.5. Your “CBD Lotion,” “CBD Pain-Relief Patch,” “CBD Tincture,” and “CBD Disposable Vape Pen” products are offered for conditions that are not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layperson can use these drugs safely for their intended purposes. FDA-approved prescription drugs which bear their FDA-approved labeling are exempt from the requirements that they bear adequate directions for use by a layperson. However, your products are not exempt from the requirement that their labeling bear adequate directions for use, 21 CFR 201.100(c)(2) and 201.115, because no FDA-approved applications are in effect for them. It is prohibited to introduce or deliver for introduction into interstate commerce a misbranded drug under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).

### **Dietary Supplement Labeling**

Information on your website and social media accounts suggests that you may intend to market your CBD products as dietary supplements. For example, a disclaimer on your website includes the statement “Cannabidiol (CBD) is a natural constituent of industrial hemp and is a dietary supplement.” You also display a photo of a CBD product with a supplement facts panel that appears to be your “CBD Tincture” (Relax version) on your social media accounts. Furthermore, you state under the disclaimer section on your “CBD Lotion,” “CBD Pain-Relief Patch,” “CBD Tincture,” and “CBD Disposable Vape Pen” products’ webpages that “Cannabidiol (CBD) . . . is a dietary supplement.” Based on these observations, it appears you intend to market your CBD products as dietary supplements. However, they cannot be dietary supplements because they do not meet the definition of a dietary supplement under sections 201(ff)(3)(B) and 201(ff)(2)(A)(i) of the FD&C Act, 21 U.S.C. 321(ff)(3)(B) and 321(ff)(2)(A)(i).

FDA has concluded based on available evidence that CBD products are excluded from the dietary supplement definition under sections 201(ff)(3)(B)(i) and (ii) of the FD&C Act, 21 U.S.C. 321(ff)(3)(B)(i) and (ii). Under those provisions, if an article (such as CBD) is an active ingredient in a drug product that has been approved under section 505 of the FD&C Act, 21 U.S.C. 355, or has been authorized for investigation as a new drug for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public, then products containing that substance are outside the definition of a dietary supplement. There is an exception if the substance was “marketed as” a dietary supplement or as a conventional food before the new drug investigations were authorized; however, based on available evidence, FDA has concluded that this is not the case for CBD.<sup>2</sup> FDA is not aware of any evidence that would call into question its current conclusion that CBD products are excluded from the dietary supplement definition under sections 201(ff)(3)(B)(i) and (ii) of the FD&C Act, but you may present FDA with any evidence that has bearing on this issue.

Furthermore, your “CBD Lotion” product’s labeling states that it is intended to be applied directly to the skin; your “CBD Pain-Relief Patch” product’s labeling states that it is intended to be applied to the body for transdermal use; and your “CBD Disposable Vape Pen” products’ labeling states that they are intended for inhalation. The FD&C Act defines the term “dietary supplement” in section 201(ff)(2)(A)(i) as a product that is



"intended for ingestion." Because these products are not intended for ingestion, this is an additional reason why your "CBD Lotion," "CBD Pain-Relief Patch," and "CBD Disposable Vape Pen" products do not meet the definition of a dietary supplement under the FD&C Act. Furthermore, with respect to your "CBD Tincture" products, the "Suggested Use" section of these products' labeling includes both "edible" uses and topical uses. To the extent that your "CBD Tincture" products are intended for a delivery method other than ingestion, as evidenced by the labeling describing topical uses, this is an additional reason why these products also do not meet the definition of a dietary supplement under the FD&C Act.

#### **Unapproved New Animal Drugs**

During a recent review of your firm's website (<https://curaleafhemp.com/collections/pet-drops>), FDA determined that your firm is marketing "Bido CBD for Pets" (Pure, Bacon and Salmon Flavor), which are unapproved new animal drugs. Based on our review of the information provided, we determined that these products are intended for use in the mitigation, treatment, or prevention of diseases in animals, which makes them drugs under section 201(g)(1)(B) of the Federal Food, Drug and Cosmetic Act (the FD&C Act), 21 U.S.C. 321(g)(1)(B). Further, as discussed below, these products are unapproved new animal drugs and marketing them violates the FD&C Act.

Examples of claims observed on your firm's website (<https://curaleafhemp.com/blogs/cbd>) that show the intended uses of these products include, but are not limited to, the following:

Found at: <https://curaleafhemp.com/blogs/cbd/reasons-to-use-cbd-oil-for-dogs>

- "Decrease compulsive behavior like biting, scratching, chewing, whining, eliminating, and other symptoms of dog separation anxiety"
- "Decrease autonomic arousal symptoms like fast/irregular heartbeat, panting, and general distressed feelings"
- "Alleviate fear feelings"
- "Prevent the longer-term health effects of anxiety"
- "CBD may help with cat anxiety" (<https://curaleafhemp.com/blogs/cbd/cbd-oil-for-cats> )
- "It's natural, safe and will allow your dog to play, eat, and do other things dogs enjoy without the symptoms of anxiety." (<https://curaleafhemp.com/blogs/cbd/cbd-for-dog-separation-anxiety>)
- "vets will prescribe puppy Xanax to pet owners which can help in certain instances but is not necessarily a desirable medication to give your dog continually. Whereas CBD oil is natural and offers similar results without the use of chemicals." (<https://curaleafhemp.com/blogs/cbd/how-much-cbd-oil-should-i-give-my-dog> )
- "Relief of seizures and neurological problems" (<https://curaleafhemp.com/blogs/cbd?page=2> )
- "Soothing of trauma and anxiety" (<https://curaleafhemp.com/blogs/cbd?page=2> )

Found at: <https://curaleafhemp.com/blogs/cbd/reasons-to-use-cbd-oil-for-dogs>

- "For dogs with arthritis and other joint issues, the American Kennel Club reports that CBD treats inflammation in the muscle tissue and joints—which works to improve the overall musculoskeletal system."
- "...this helps take pressure away from the surrounding nerve endings and directly reduces pain."

Found at: <https://curaleafhemp.com/blogs/cbd?page=3>



- "Pain relief from cancer or after surgery"
- "Relief of muscle spasms"
- "Recently published research confirms that CBD helps dogs with osteoarthritis. All dogs in the trial showed marked improvement in their overall activity levels and apparent pain levels. So it's believed that CBD would provide the same results for cats with arthritis or inflammation."

Found at: <https://curaleafhemp.com/blogs/cbd/cbd-oil-for-cats>

• "Diabetes"

Found at: <https://curaleafhemp.com/blogs/cbd/is-cbd-oil-safe-for-dogs>

"What are the benefits of using CBD oil for your pets?...."

- Pain relief from arthritis and aging"

Found at: <https://curaleafhemp.com/blogs/cbd/cannabis-oil-dog-cancer>

- "CBD oil can help relieve cancer pain and spasms"
- "CBD oil may slow the growth of cancer"

Found at: <https://curaleafhemp.com/blogs/cbd?page=9>

- "...it has been found to assist in the reduction of tumor size while stunting the potential spreading of cancer through the body."

• "Chemotherapy, radiation treatments, and surgery can quickly push into the tens of thousands of dollars. While you may not be able to afford such cancer treatments for your dog, CBD oil is a viable and inexpensive alternative."

- "For dogs experiencing pain, spasms, anxiety, nausea or inflammation often associated with cancer treatments, CBD (aka cannabidiol) may be a source of much-needed relief."

(<https://curaleafhemp.com/blogs/cbd?page=3>)

- "...CBD oil has been clinically shown to help manage the symptoms of cancer treatment, which can improve a patient's quality of life." (<https://curaleafhemp.com/blogs/cbd?page=3>)

Found at: <https://curaleafhemp.com/blogs/cbd/how-much-cbd-oil-should-i-give-my-dog>

- "Many dogs, especially those with thinner, shorter coats, suffer from skin conditions. Whether due to allergies or the weather, CBD oil can help improve the overall quality of your dog's skin."

Because the products are intended to mitigate, treat, or prevent disease in animals, they are drugs within the meaning of section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B). Further, these products are "new animal drugs" under section 201(v) of the FD&C Act, 21 U.S.C. 321(v), because they are not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling.

To be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&C Act, 21 U.S.C. 360b, 360ccc, and 360ccc-l. These products are not approved or index listed by the FDA, and therefore these products are considered unsafe under section 512(a) of the FD&C Act, 21 U.S.C. 360b(a), and adulterated under section 501(a)(5) of the FD&C Act, 21 U.S.C. 351(a)(5). Introduction of an adulterated drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).



The violations cited in this letter are not intended to be an all-inclusive statement of violations that exist in connection with your marketed products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations.

You should take prompt action to correct the violations cited in this letter. Failure to promptly correct these violations may result in legal action without further notice, including, without limitation, seizure and injunction.

Within fifteen working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.

Your response should be sent to U.S. Food and Drug Administration, CDER/OC/Office of Unapproved Drugs and Labeling Compliance, 10903 New Hampshire Avenue, WO51, Silver Spring, MD 20993-0002 or by email to [FDAADVISORY@fda.hhs.gov](mailto:FDAADVISORY@fda.hhs.gov).

Sincerely,

/s/

Donald D. Ashley

Director

Office of Compliance

Center for Drug Evaluation and Research

Food and Drug Administration

/s/

Eric Nelson

Director

Office of Compliance

Center for Veterinary Medicine

Food and Drug Administration

[1] Full product list: CBD Tincture Digest, CBD Tincture Uplift, CBD Tincture Relieve, CBD Tincture Revive, and CBD Tincture Relax; CBD Disposable Vape Pen Digest, CBD Disposable Vape Pen Uplift, CBD Disposable Vape Pen Relieve, CBD Disposable Vape Pen Revive, and CBD Disposable Vape Pen Relax; and Bido CBD for Pets Bacon, Bido CBD for Pets Pure, and Bido CBD for Pets Salmon.

[2] CBD is the active ingredient in the approved drug product Epidiolex. Furthermore, the existence of substantial clinical investigations regarding CBD has been made public. For example, two such substantial clinical investigations include GW Pharmaceuticals' investigations regarding Sativex and Epidiolex. (See [Sativex Commences US Phase II/III Clinical Trial in Cancer Pain](https://www.gwpharm.com/about/news/sativex-commences-us-phase-iii-clinical-trial-cancer-pain) (<https://www.gwpharm.com/about/news/sativex-commences-us-phase-iii-clinical-trial-cancer-pain>) and <http://www.fda.gov/about-fda/website-policies/website-disclaimer>) and [GW Pharmaceuticals Receives Investigational New Drug \(IND\) from FDA for Phase 2/3 Clinical Trial of Epidiolex in the Treatment of Dravet Syndrome](http://www.fda.gov/about-fda/website-policies/website-disclaimer) (<http://www.fda.gov/about-fda/website-policies/website-disclaimer>)). FDA considers a substance to be "authorized for investigation as a new drug"



if it is the subject of an Investigational New Drug application (IND) that has gone into effect. Under FDA's regulations [21 CFR 312.2], unless a clinical investigation meets the limited criteria in that regulation, an IND is required for all clinical investigations of products that are subject to section 505 of the FD&C Act.

➤ More Warning Letters (/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters)



**WARNING LETTER**

**Dr. G's Marine Aquaculture, Inc.**

**MARCS-CMS 606979 – APRIL 15, 2020**

**Product:**

Animal & Veterinary

**Recipient:**

Ms. Elena Ninoua-Gonzalez

Dr. G's Marine Aquaculture, Inc.

20841 Johnson Street, 110

Pembroke Pines, FL 33029

United States

✉ [drgsphyto@gmail.com](mailto:drgsphyto@gmail.com) (mailto:drgsphyto@gmail.com)

**Issuing Office:**

Center for Veterinary Medicine

United States

**WARNING LETTER**

Date: April 15, 2020

RE: Unapproved Chloroquine Phosphate Product

Dear Ms. Ninoua-Gonzalez:

This is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the internet address <http://www.dragsmarineaquaculture.com> in April 2020. The FDA has observed that your website offers Dr. G's Anti-Parasitic Caviar for sale in the United States. Based on our review, this product is adulterated. The introduction or delivery for introduction into interstate commerce of any food or drug that is adulterated is a prohibited act. (Section 301(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. § 321(a)].)

Your Dr. G's Anti-Parasitic Caviar product is a drug under Section 201(g)(1)(B) of the FD&C Act [21 U.S.C. § 321(g)(1)(B)] because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals. Some examples of the claims on your website, where you sell Dr. G's Anti-Parasitic Caviar, <http://www.dragsmarineaquaculture.com/anti-parasitic-caviar-detail.cfm>, that establish the intended uses of your product include:



- "Treats Ich, Brooklynella, Uronema, Crypto, Oodinium and many more Ornamental Fish Parasites."
- "Effective new treatment for several forms of marine and freshwater Parasites, that can harm or kill your fish."
- "Treats your Fish, Not your Water!"
- "Our unique formula provides the Anti-Parasitic efficiency of Chloroquine plus the premium nutritional value of Dr.G's Caviar MAX, made with the finest and freshest ingredients."

Dr. G's Anti-Parasitic Caviar is intended for use in fish, a "minor species," as defined in section 201(o) of the FD&C Act [21 U.S.C. § 321(o)]. Therefore, your Dr. G's Anti-Parasitic Caviar product is a new animal drug under section 201(v) of the FD&C Act [21 U.S.C. § 321(v)] because it is not the subject of a final FDA regulation published through notice and comment rulemaking finding that the drug has been generally recognized among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling. To be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or a listing on the Index of Legally Marketed Unapproved New Animal Drugs for Minor Species ("index listing") under section 512, 571, or 572 of the FD&C Act [21 U.S.C. § 360b, 360ccc, or 360ccc-1], respectively. Dr. G's Anti-Parasitic Caviar has not been approved, conditionally approved, or index listed. New animal drugs that lack the required approval or index listing are "unsafe" and "adulterated" under sections 512(a) and 501(a)(5) of the FD&C Act [21 U.S.C. §§ 360b(a) and 351(a)(5)]. Introduction of an adulterated animal drug into interstate commerce is prohibited under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].

Your product's labeling includes the claim, "provides the Anti-Parasitic efficiency of Chloroquine," demonstrating the intended use of chloroquine as a drug. Chloroquine is a new animal drug under section 201(v) of the FD&C Act. It has not been approved, conditionally approved or index listed for use in ornamental fish. Therefore, chloroquine is an unsafe new animal drug within the meaning of section 512(a) of the FD&C Act.

Your Dr. G's Anti-Parasitic Caviar is accompanied by labeling including the statement, "To 'Treat' Parasitic infections, use as regular food twice a day for up to 3 weeks. To 'Prevent' Parasitic infections, use as regular food twice a day for up to 3 weeks." As defined by section 201(w) of the FD&C Act [21 U.S.C. § 321(w)], an article which is intended for use for food for animals other than man and which is intended for use as a substantial source of nutrients in the diet of the animals is an "animal feed." To the extent your Dr. G's Anti-Parasitic Caviar is an animal feed that contains the unsafe new animal drug chloroquine, it is an unsafe animal feed within the meaning of section 512(a)(2) of the FD&C Act [21 U.S.C. 360b(a)(2)]. Such an unsafe animal feed is an adulterated drug within the meaning of section 501(a)(6) of the FD&C Act [21 U.S.C. 351(a)(6)].

Finally, to the extent your Dr. G's Anti-Parasitic Caviar is a "food," as defined by section 201(f) of the FD&C Act [21 U.S.C. § 321(f)], it is an adulterated food within the meaning of section 402(a)(2)(C)(ii) of the FD&C Act [21 U.S.C. 342(a)(2)(C)(ii)], which states that a food is adulterated if it bears or contains a new animal drug that is unsafe within the meaning of section 512 of the FD&C Act. As noted above, chloroquine is an unsafe new animal drug within the meaning of section 512(a) of the FD&C Act. Introduction of an adulterated food into interstate commerce is prohibited under section 301(a) of the FD&C Act.

The violations cited in this letter are not intended to be an all-inclusive statement of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&C Act and FDA's implementing regulations.

You should take prompt action to correct the violations cited in this letter. Failure to promptly correct these violations may result in legal action without further notice, including, without limitation, seizure and injunction.



**Within 48 hours, please send an email to the contact person below**, describing the specific steps you have taken to correct these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within 48 hours, state the reason for the delay and the time within which you will complete the correction. If you do not believe that your products are in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.

Your response should be sent via e-mail to Dr. Vic Boddie at [Vic.Boddie@fda.hhs.gov](mailto:Vic.Boddie@fda.hhs.gov). If you have any questions about this letter, please contact Dr. Boddie at 240-402-5618.

Sincerely,  
/S/

Mr. Eric M. Nelson  
Director, Division of Compliance  
Center for Veterinary Medicine  
Food and Drug Administration

---

<sup>4</sup> Your labeling states that your Dr. G's Anti-Parasitic Caviar contains Dr. G's Caviar MAX (capelin (*Mallotus villosus*) eggs), Dr. G's Reef Essentials vitamins and amino acids, and garlic.

🔍 More Warning Letters ([/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters](#))